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【要約】 
The effect on gastric emptying of telaprevir-based triple 
therapy for chronic hepatitis C patients 
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Abstract 
Aim: Telaprevir-based triple therapy (telaprevir, pegylated-interferon, and ribavirin) is a 
standard treatment for chronic hepatitis C patients. Loss of appetite and nausea are 
major adverse events that may lead to discontinuation of treatment or a decrease in the 
dose of the drugs. Gastric emptying (GE) is a major function of the stomach and its 
disruption is related to various diseases. In this study, we evaluated food intake in 
telaprevir-based triple therapy and its relation to GE. 
Methods: From September 2012 to October 2013, 17 patients (54.1 ± 8.4 years old) 
received telaprevir combined with pegylated interferon plus ribavirin at Chiba 
University Hospital. The study was approved by Chiba University Hospital Institutional 
Review Board (UMIN000012279). The food intake and body weight of each patient 
were determined daily. The GE study was carried out using the 13C-acetate breath test 
and GE time was expressed as the peak time of 
13
CO2 excretion (Tmax). GE was 
evaluated three times at 0, 1, and 2 weeks after the start of treatment. At the same time 
points, the acyl-ghrelin, desacyl-ghrelin and leptin levels also were determined. 
Results: The average food intake was 1,851 ± 91, 1,338 ± 537 and 1,453 ± 537 kcal at 0, 
1, and 2 weeks after the start of treatment, respectively, showing a significant decrease 
compared to that before treatment (p < 0.01 and p <0.05, paired t-test). Loss of body 
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weight was observed at 1 and 2 weeks after the start of treatment, and this was  
significant (-3.2 ± 2.6 % and -3.6 ± 2.1 %, p < 0.01 and p <0.05, paired t-test). The 
averages of Tmax values at 0, 1, and 2 weeks after the start of treatment were 48.4 ± 
14.3 min, 56.9 ± 18.4 min and 58.0 ± 19.9 min, respectively, indicating that the 
telaprevir-based treatment delayed GE. There was a significant difference between 
baseline and 1 week after the start of treatment (p<0.05, paired t-test). Food intake 
(kcal) showed a good correlation with the decrease of Tmax values (minutes) (Pearson’s 
correlation test, r = -0.49, p < 0.05). The levels of acyl-ghrelin and desacyl-ghrelin did 
not a change significantly change, in contrast, the leptin level at 2 weeks after the start 
of treatment (5.3 ± 2.4 ng/ml) was lower than that at baseline(7.5 ± 3.3 ng/ml) a 
significant difference (p < 0.01, paired t-test). 
Conclusions: Telaprevir-based triple therapy for chronic hepatitis C patients caused 
reduced food intake and a loss of body weight, and worsened GE. The deterioration of 
GE is a major cause of reduced food intake. The use of drugs to improve GE could 
avoid the loss of appetite and body weight, which might result in raising the rate of 
accomplishing treatment and achieving a sustained virological response.  
 
Oyamada A et al. 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatology international 
平成 25年 12月 投稿中 
  
